The rtPA (Alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study

Stroke

Volumn 31, Issue 4, 2000, Pages 811-816

  Clark, Wayne M ^a,e   Albers, Gregory W ^b   Madden, Kenneth P ^c   Hamilton, Scott ^d  

^a Oregon Stroke Center   (United States)

^b Stanford California and Cofounder   (United States)

^c MARSHFIELD CLINIC   (United States)

^d GENENTECH INC   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Stroke; Therapy; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0034120507     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.4.811     Document Type: Article

References (10)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Fieshchi C, Toni D, Lesaffre E, von Kummer R, Boysen G. Bluhmki E, Hoxter G, Mahagne MH, Hennerici M (for the ECASS Study Group). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995;274: 1017-1025.
3. Clark W, Wissman S, Albers G, Jhamandas J, Madden K. The ATLANTIS rt-PA (alteplase) 3-5 Hour Acute Stroke Trial Part B: results of a double-blind, placebo-controlled multicenter study. JAMA. In Press.
4. Brott T, Adams H. Olinger C. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
5. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J, for the NINDS TPA Stroke Study Group. Improved reliability of the NIH Stroke Scale using video training. Stroke. 1994;25: 2220-2226.
6. Mahoney F, Barthel D. Functional evaluation: Barthel Index. Md State Med J. 1965;14:61-65.
7. Jennett B, Bond M. Assessment of outcome after severe brain damage: a practical scale. Lancet. 1975;1:480-484.
8. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28:2119-2125.
9. Hacke W, Kaste M, Fieshchi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnon G, Schneider D, Diez-Tejedor E, Trouillas P (Second European-Australasian Acute Stroke Study Investigators). Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
10. Albers G, the STARS Investigators. Prospective, monitored, multicenter, post-approval experience with intravenous t-PA for treatment of acute stroke: the Standard Treatment with Activase to Reverse Stroke (STARS) Study. Stroke. 1999;30:244. Abstract 77.